RGEN
Repligen CorporationNASDAQHealthcare$117.78-0.46%ClosedMarket Cap: $6.63B
As of 2026-04-06
Valuation
P/E (TTM)
135.70
PEG
0.47
P/B
3.16
P/S
8.99
EV/EBITDA
38.26
DCF Value
$29.86
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
50.9%
Operating Margin
7.6%
Net Margin
6.6%
ROE
2.4%
ROA
3.4%
ROIC
1.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $197.9M | 47.2% | $18.6M | $13.3M | $0.23 | — |
| FY 2025 | $738.3M | 47.1% | $59.6M | $48.9M | $0.86 | — |
| Q3 2025 | $188.8M | 53.2% | $16.8M | $14.9M | $0.26 | — |
| Q2 2025 | $182.4M | 50.0% | $13.9M | $14.9M | $0.26 | — |
| Q1 2025 | $169.2M | 53.6% | $6.6M | $5.8M | $0.10 | — |
| Q4 2024 | $167.5M | 23.2% | $-36.5M | $-33.9M | $-0.60 | — |
| FY 2024 | $634.4M | 43.3% | $-35.1M | $-25.5M | $-0.46 | — |
| Q3 2024 | $154.9M | 50.0% | $-7.8M | $-654.0K | $0.32 | — |
| Q2 2024 | $158.8M | 46.2% | $7.4M | $5.7M | $0.06 | — |
| Q1 2024 | $153.2M | 50.1% | $3.8M | $3.3M | $0.04 | — |
| Q4 2023 | $155.7M | 43.4% | $-887.0K | $-25.5M | $-0.46 | — |
| FY 2023 | $632.4M | 44.0% | $47.7M | $35.6M | $0.63 | — |